Severaj Rucita, Gounden Verena
Discipline of Chemical Pathology, Faculty of Laboratory Medicine, National Health Laboratory Service and University of KwaZulu-Natal, Durban, South Africa.
Afr J Lab Med. 2024 May 6;13(1):2302. doi: 10.4102/ajlm.v13i1.2302. eCollection 2024.
Diabetic monitoring and treatment guidelines are easily accessible, but compliance is poor in KwaZulu-Natal. The coronavirus disease 2019 (COVID-19) pandemic had a devastating impact on diabetic healthcare, both directly and through public health interventions.
This study aimed to close the gaps in knowledge concerning glycated haemoglobin (HbA1c) test utilisation and how this was affected by the COVID-19 lockdown in KwaZulu-Natal.
We reviewed HbA1c test volumes and results from public health facilities in the 11 health districts in KwaZulu-Natal, South Africa. We compared testing trends and glycaemic control between two 10-month study periods before (March 2019 - December 2019) and during (March 2020 - December 2020) the COVID-19 pandemic.
The number of HbA1c tests performed decreased 6.1% during the pandemic period, with 173 760 HbA1c tests performed in 2019 and 163 236 HbA1c tests performed in 2020. There was a statistically significant increase in the average HbA1c level during the pandemic (mean HbA1c level in the pre-pandemic period: 70.5 mmol/mol [8.6%] versus mean HbA1c level in the pandemic period: 72.7 mmol/mol [8.8%]; -value < 0.001). Of patients with suboptimal HbA1c results (83 421 in 2019, 83 259 in 2020), 11 656 (14.0%) in 2019 and 10 086 (12.1%) in 2020 had more than one HbA1c test performed during the study period.
The COVID-19 pandemic impacted glycaemic monitoring in KwaZulu-Natal with lower HbA1c test volumes and worse glycaemic control seen during the pandemic. HbA1c testing practices are not in keeping with recommended guidelines.
The study demonstrates that the COVID-19 pandemic impacted HbA1c utilisation in KwaZulu-Natal. Importantly, HbA1c testing practices in KwaZulu-Natal are not in keeping with Society for Endocrinology, Metabolism and Diabetes of South Africa guidelines regarding the monitoring of diabetic patients, and this requires more attention for future diabetic healthcare interventions.
糖尿病监测和治疗指南很容易获取,但夸祖鲁 - 纳塔尔省的依从性较差。2019年冠状病毒病(COVID - 19)大流行对糖尿病医疗保健产生了毁灭性影响,包括直接影响以及通过公共卫生干预措施产生的影响。
本研究旨在填补关于糖化血红蛋白(HbA1c)检测使用情况的知识空白,以及了解其在夸祖鲁 - 纳塔尔省是如何受到COVID - 19封锁影响的。
我们回顾了南非夸祖鲁 - 纳塔尔省11个卫生区公共卫生设施的HbA1c检测量和结果。我们比较了COVID - 19大流行之前(2019年3月 - 2019年12月)和期间(2020年3月 - 2020年12月)两个为期10个月的研究期间的检测趋势和血糖控制情况。
大流行期间进行的HbA1c检测数量减少了6.1%,2019年进行了173760次HbA1c检测,2020年进行了163236次HbA1c检测。大流行期间平均HbA1c水平有统计学意义的升高(大流行前时期的平均HbA1c水平:70.5 mmol/mol [8.6%],而大流行期间的平均HbA1c水平:72.7 mmol/mol [8.8%];P值<0.001)。在HbA1c结果不理想的患者中(2019年有83421例,2020年有83259例),2019年有11656例(14.0%),2020年有10086例(12.1%)在研究期间进行了不止一次HbA1c检测。
COVID - 19大流行对夸祖鲁 - 纳塔尔省的血糖监测产生了影响,大流行期间HbA1c检测量较低且血糖控制更差。HbA1c检测实践不符合推荐指南。
该研究表明COVID - 19大流行影响了夸祖鲁 - 纳塔尔省HbA1c的使用。重要的是,夸祖鲁 - 纳塔尔省的HbA1c检测实践不符合南非内分泌、代谢和糖尿病学会关于糖尿病患者监测的指南,这在未来糖尿病医疗干预中需要更多关注。